Acumen Pharmaceuticals (ABOS) Common Equity (2020 - 2026)

Acumen Pharmaceuticals (ABOS) has 7 years of Common Equity data on file, last reported at $87.5 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 43.75% year-over-year to $87.5 million; the trailing twelve-month figure through Mar 2026 stood at $87.5 million (down 43.75% YoY), and the FY2025 full-year result was $70.4 million, down 61.26% from the prior year.
• Common Equity rose to $87.5 million in Q1 2026, from $70.4 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $280.3 million in Q3 2023 to a low of $70.4 million in Q4 2025.
• A 5-year average of $184.2 million and a median of $188.8 million in 2022 frame the typical range for Common Equity.
• Across the five-year window, Common Equity soared 575.32% in 2022 and plunged 61.26% in 2025, its largest moves.
• Tracing ABOS's Common Equity over 5 years: stood at $188.8 million in 2022, then surged by 41.42% to $267.0 million in 2023, then tumbled by 31.9% to $181.8 million in 2024, then sank by 61.26% to $70.4 million in 2025, then increased by 24.2% to $87.5 million in 2026.
• Business Quant data shows ABOS's Common Equity at $87.5 million in Q1 2026, $70.4 million in Q4 2025, and $93.2 million in Q3 2025.